2015 Newsroom

Keyword Search
 
2014 | 2013 | 2012
DateTitle 
01/27/15Intrexon Announces Closing of $116 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
GERMANTOWN, Md., Jan. 27, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today the closing of its previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 562,500 shares of common stock at the public offering price of $27.00 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by Intrexon to 4,312,500 sha... 
Printer Friendly Version
01/26/15Intrexon to Acquire Remaining Stake in Exemplar Genetics
Intrexon Collaborators Obtain Access to Premier Pipeline of Large Animal Research Models and Custom Animal Development GERMANTOWN, Md. and SIOUX CENTER, Iowa, Jan. 26, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has launched a tender offer to acquire the remaining stake in Exemplar Genetics, a company committed to enabling the study of life-threatening human diseases.  Utilizing its proprietary technologies in animal genetics, Exe... 
Printer Friendly Version
01/21/15Intrexon Prices Public Offering of Common Stock
GERMANTOWN, Md., Jan. 21, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has priced its previously announced underwritten public offering of common stock consisting of 3,750,000 shares at a public offering price of $27.00 per share.  Gross proceeds to Intrexon from this offering are expected to be approximately $101.25 million and Intrexon intends to use the net proceeds from this offering for general corporate purposes as well as fo... 
Printer Friendly Version
01/20/15Intrexon Announces Proposed Public Offering of Common Stock
GERMANTOWN, Md., Jan. 20, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today it has commenced an underwritten public offering of up to $150 million of shares of its common stock.  Intrexon intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of the common stock offered in the public offering.  All of the shares in the offering will be sold by Intrexon. J.P. Morgan and BofA Merrill Lynch are actin... 
Printer Friendly Version
01/13/15Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact
Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies Combined Technologies to Leapfrog Clinical Pipeline of Next Generation Therapies Using Synthetic and Personalized Immunology GERMANTOWN, Md., BOSTON, and HOUSTON, Jan. 13, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (NASDAQ: ZIOP), today announced a ... 
Printer Friendly Version
01/06/15Intrexon to Present at the 2015 J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Jan. 6, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14th, at 8:30 a.m. Pacific Standard Time at the Westin St. Francis in San Francisco. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in... 
Printer Friendly Version

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds |

Share Page

X
| E-mail Alerts E-mail Alerts | IR Contacts Contact US | Financial Tear Sheet Financial Tear Sheet